Standard BioTools published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting revenue of USD 85.33 million, down 6%. The company posted a net loss of USD 74.9 million, while net loss from continuing operations was USD 58.83 million. Consumables revenue fell 11% to USD 36.25 million, which management attributed to macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments. Selling, general and administrative expense rose 7% to USD 109.86 million, driven mainly by higher personnel-related costs, including increased bonus expense and labor costs and additional stock-based compensation. Standard BioTools said Illumina agreed to acquire its SomaScan business for up to USD 425 million, including USD 350 million upfront and up to USD 75 million in earnout payments, with the transaction closing in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Standard BioTools Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108326), on March 16, 2026, and is solely responsible for the information contained therein.